References
1 AJ Moss, WJ Hall, DS Cannom, JP Daubert, SL Higgins, H Klein, et al.,
Improved survival with an implanted defibrillator in patients with
coronary disease at high risk for ventricular arrhythmia. Multicenter
automatic defibrillator implantation trial investigators. N Engl J Med
335(26) (1996) 1933-1940.
2 SH Hohnloser, KH Kuck, P Dorian, RS Roberts, JR Hampton, R Hatala, et
al., Prophylactic use of an implantable cardioverter-defibrillator after
acute myocardial infarction. N Engl J Med 351(24) (2004) 2481-2488.
3 SL Rosenkaimer, I El-Battrawy, TC Dreher, S Gerhards, S Roger, J
Kuschyk, et al., The wearable cardioverter-defibrillator: Experience in
153 patients and a long-term follow-up. J Clin Med 9(3) (2020).
4 M Winther-Jensen, J Kjaergaard, JF Lassen, L Kober, C Torp-Pedersen,
SM Hansen, et al., Implantable cardioverter defibrillator and survival
after out-of-hospital cardiac arrest due to acute myocardial infarction
in denmark in the years 2001-2012, a nationwide study. Eur Heart J Acute
Cardiovasc Care 6(2) (2017) 144-154.
5 AM Feldman, H Klein, P Tchou, S Murali, WJ Hall, D Mancini, et al.,
Use of a wearable defibrillator in terminating tachyarrhythmias in
patients at high risk for sudden death: Results of the wearit/biroad.
Pacing Clin Electrophysiol 27(1) (2004) 4-9.
6 B Kovacs, S Reek, AM Saguner, N Krasniqi, U Eriksson and F Duru,
Outcomes during and after the use of the wearable
cardioverter-defibrillator in a tertiary-care and a regional hospital in
switzerland. Swiss Med Wkly 149((2019) w20136.
7 JP Piccini, Sr., LA Allen, PJ Kudenchuk, RL Page, MR Patel, MP
Turakhia, et al., Wearable cardioverter-defibrillator therapy for the
prevention of sudden cardiac death: A science advisory from the american
heart association. Circulation 133(17) (2016) 1715-1727.
8 JE Olgin, MJ Pletcher, E Vittinghoff, J Wranicz, R Malik, DP Morin, et
al., Wearable cardioverter-defibrillator after myocardial infarction. N
Engl J Med 379(13) (2018) 1205-1215.
9 JW Erath, B Assmus, A Burch, D Bondermann, AM Russo and V Kutyifa,
Sustained ventricular tachyarrhythmia termination in a large cohort of
women using wearable cardioverter-defibrillators. JACC Clin
Electrophysiol 6(9) (2020) 1187-1188.
10 I Goldenberg, JW Erath, AM Russo, AE Burch, B Assmus, D Bonderman, et
al., Sex differences in arrhythmic burden with the wearable
cardioverter-defibrillator. Heart Rhythm 18(3) (2021) 404-410.
11 P Ponikowski, AA Voors, SD Anker, H Bueno, JGF Cleland, AJS Coats, et
al., 2016 esc guidelines for the diagnosis and treatment of acute and
chronic heart failure: The task force for the diagnosis and treatment of
acute and chronic heart failure of the european society of cardiology
(esc)developed with the special contribution of the heart failure
association (hfa) of the esc. Eur Heart J 37(27) (2016) 2129-2200.
12 P Riis, Perspectives on the fifth revision of the declaration of
helsinki. JAMA 284(23) (2000) 3045-3046.
13 HU Klein, I Goldenberg and AJ Moss, Risk stratification for
implantable cardioverter defibrillator therapy: The role of the wearable
cardioverter-defibrillator. Eur Heart J 34(29) (2013) 2230-2242.
14 S Reek, H Burri, PR Roberts, C Perings, AE Epstein, HU Klein, et al.,
The wearable cardioverter-defibrillator: Current technology and evolving
indications. Europace 19(3) (2017) 335-345.
15 FM Kusumoto, KR Bailey, AS Chaouki, AJ Deshmukh, S Gautam, RJ Kim, et
al., Systematic review for the 2017 aha/acc/hrs guideline for management
of patients with ventricular arrhythmias and the prevention of sudden
cardiac death: A report of the american college of cardiology/american
heart association task force on clinical practice guidelines and the
heart rhythm society. Circulation 138(13) (2018) e392-e414.
16 P Ponikowski, AA Voors, SD Anker, H Bueno, JG Cleland, AJ Coats, et
al., 2016 esc guidelines for the diagnosis and treatment of acute and
chronic heart failure: The task force for the diagnosis and treatment of
acute and chronic heart failure of the european society of cardiology
(esc). Developed with the special contribution of the heart failure
association (hfa) of the esc. Eur J Heart Fail 18(8) (2016) 891-975.
17 G Amit, M Suleiman, Y Konstantino, D Luria, M Kazatsker, I Chetboun,
et al., Sex differences in implantable cardioverter-defibrillator
implantation indications and outcomes: Lessons from the nationwide
israeli-icd registry. Europace 16(8) (2014) 1175-1180.
18 AA Merz and S Cheng, Sex differences in cardiovascular ageing. Heart
102(11) (2016) 825-831.
19 NK Wassnig, M Gunther, S Quick, C Pfluecke, F Rottstadt, SJ
Szymkiewicz, et al., Experience with the wearable
cardioverter-defibrillator in patients at high risk for sudden cardiac
death. Circulation 134(9) (2016) 635-643.
20 JE Olgin, BK Lee, E Vittinghoff, DP Morin, S Zweibel, E Rashba, et
al., Impact of wearable cardioverter-defibrillator compliance on
outcomes in the vest trial: As-treated and per-protocol analyses. J
Cardiovasc Electrophysiol 31(5) (2020) 1009-1018.
21 R Garcia, N Combes, P Defaye, K Narayanan, L Guedon-Moreau, S Boveda,
et al., Wearable cardioverter-defibrillator in patients with a transient
risk of sudden cardiac death: The wearit-france cohort study. Europace
23(1) (2021) 73-81.
22 A Auricchio, H Klein, CJ Geller, S Reek, MS Heilman and SJ
Szymkiewicz, Clinical efficacy of the wearable
cardioverter-defibrillator in acutely terminating episodes of
ventricular fibrillation. Am J Cardiol 81(10) (1998) 1253-1256.
23 MK Chung, SJ Szymkiewicz, M Shao, E Zishiri, MJ Niebauer, BD Lindsay,
et al., Aggregate national experience with the wearable
cardioverter-defibrillator: Event rates, compliance, and survival. J Am
Coll Cardiol 56(3) (2010) 194-203.
24 ET Zishiri, S Williams, EM Cronin, EH Blackstone, SG Ellis, EE
Roselli, et al., Early risk of mortality after coronary artery
revascularization in patients with left ventricular dysfunction and
potential role of the wearable cardioverter defibrillator. Circ Arrhythm
Electrophysiol 6(1) (2013) 117-128.